ES2533788T3 - Compuestos inhibidores de PI3K de tipo purina y métodos de uso - Google Patents

Compuestos inhibidores de PI3K de tipo purina y métodos de uso Download PDF

Info

Publication number
ES2533788T3
ES2533788T3 ES09755767.2T ES09755767T ES2533788T3 ES 2533788 T3 ES2533788 T3 ES 2533788T3 ES 09755767 T ES09755767 T ES 09755767T ES 2533788 T3 ES2533788 T3 ES 2533788T3
Authority
ES
Spain
Prior art keywords
morpholino
purin
alkylene
methyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09755767.2T
Other languages
English (en)
Spanish (es)
Inventor
Georgette Castanedo
Irina Chuckowree
Adrian Folkes
Daniel P. Sutherlin
Nan Chi Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2533788T3 publication Critical patent/ES2533788T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09755767.2T 2008-05-30 2009-05-29 Compuestos inhibidores de PI3K de tipo purina y métodos de uso Active ES2533788T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5755908P 2008-05-30 2008-05-30
US57559 2008-05-30
PCT/US2009/045603 WO2009146406A1 (en) 2008-05-30 2009-05-29 Purine pi3k inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
ES2533788T3 true ES2533788T3 (es) 2015-04-14

Family

ID=41017038

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09755767.2T Active ES2533788T3 (es) 2008-05-30 2009-05-29 Compuestos inhibidores de PI3K de tipo purina y métodos de uso

Country Status (14)

Country Link
US (2) US8158624B2 (enExample)
EP (1) EP2279188B1 (enExample)
JP (1) JP2011521968A (enExample)
KR (1) KR20110042153A (enExample)
CN (1) CN102105474B (enExample)
AU (1) AU2009251291B2 (enExample)
BR (1) BRPI0909614A2 (enExample)
CA (1) CA2721851A1 (enExample)
ES (1) ES2533788T3 (enExample)
IL (1) IL208838A0 (enExample)
MX (1) MX2010012583A (enExample)
RU (1) RU2509081C2 (enExample)
WO (1) WO2009146406A1 (enExample)
ZA (1) ZA201007524B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
ES2537624T3 (es) * 2007-10-26 2015-06-10 F. Hoffmann-La Roche Ag Derivados purina útiles como inhibidores de la quinasa PI3
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
JP5465318B2 (ja) 2009-04-03 2014-04-09 ベラステム・インコーポレーテッド キナーゼ阻害剤としてのピリミジン置換プリン化合物
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2010136491A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
KR101447789B1 (ko) * 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CA2802808A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use
JP5954838B2 (ja) * 2010-09-14 2016-07-20 エクセリクシス， インク． Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2820078C (en) * 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2014107713A (ru) * 2011-07-28 2015-09-10 Дженентек, Инк Модель рака молочной железы у животных, кроме человека, с активируемым pik3ca h1047r
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
BR112014009890A2 (pt) * 2011-10-28 2020-10-27 Novartis Ag derivados de purina e seu uso no tratamento de doença
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
CN103936742B (zh) * 2013-01-17 2017-05-03 程鹏 含嘌呤基的新型pi3k抑制剂及其制备方法和应用
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20210145303A (ko) * 2013-05-02 2021-12-01 에프. 호프만-라 로슈 아게 Cb2 수용체 작용제로서의 퓨린 유도체
TW201520215A (zh) * 2013-05-13 2015-06-01 Daiichi Sankyo Co Ltd Ｎ－□啉基嘌呤衍生物之製造方法
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2926596C (en) * 2013-10-16 2020-07-14 Shanghai Yingli Pharmaceutical Co., Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
CN103804380B (zh) * 2014-01-24 2016-05-18 温州医科大学 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3233054T3 (da) * 2014-12-17 2021-08-02 Pfizer Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration
KR20170131444A (ko) 2015-03-30 2017-11-29 다이이찌 산쿄 가부시키가이샤 6-모르폴리닐-2-피라졸릴-9h-푸린 유도체 및 pi3k 저해제로서의 이들의 용도
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CA2983042C (en) * 2015-04-21 2020-01-07 Lijuan Chen Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JPWO2018062382A1 (ja) * 2016-09-29 2019-07-11 第一三共株式会社 ［２−（１−メチル−１ｈ−ピラゾール−４−イル）−６−（モルホリン−４−イル）−９ｈ−プリン−８−イル］［４−（モルホリン−４−イル）ピペリジン−１−イル］メタノン及びその製薬上許容される塩の結晶
CA3045596C (en) 2016-12-02 2022-08-23 Daiichi Sankyo Company, Limited Endo-.beta.-n-acetylglucosaminidase
SG11202103118PA (en) 2018-09-27 2021-04-29 Shanghai Yingli Pharmaceutical Co Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
UY38912A (es) * 2019-10-09 2021-05-31 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
CN111875606B (zh) * 2020-07-20 2023-04-07 武汉工程大学 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN117777134B (zh) * 2022-12-19 2025-02-25 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) * 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
CN100345830C (zh) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
US6949644B2 (en) * 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US7189730B2 (en) * 2001-12-18 2007-03-13 Cv Therapeutics, Inc. A2A adenosine receptor antagonists
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004021979A2 (en) * 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
JP4768265B2 (ja) * 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
TW200510394A (en) * 2003-05-29 2005-03-16 Synta Pharmaceuticals Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
JP2010522722A (ja) * 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
CA2682019C (en) * 2007-03-28 2016-08-09 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
ES2537624T3 (es) * 2007-10-26 2015-06-10 F. Hoffmann-La Roche Ag Derivados purina útiles como inhibidores de la quinasa PI3
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP5465318B2 (ja) * 2009-04-03 2014-04-09 ベラステム・インコーポレーテッド キナーゼ阻害剤としてのピリミジン置換プリン化合物
US8173650B2 (en) * 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
WO2010136491A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
CA2802808A1 (en) * 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use

Also Published As

Publication number Publication date
EP2279188B1 (en) 2015-01-28
JP2011521968A (ja) 2011-07-28
KR20110042153A (ko) 2011-04-25
IL208838A0 (en) 2011-01-31
BRPI0909614A2 (pt) 2015-09-22
CN102105474A (zh) 2011-06-22
MX2010012583A (es) 2011-02-24
US8158624B2 (en) 2012-04-17
US20120135988A1 (en) 2012-05-31
AU2009251291B2 (en) 2013-05-02
US8445487B2 (en) 2013-05-21
ZA201007524B (en) 2012-01-25
AU2009251291A1 (en) 2009-12-03
EP2279188A1 (en) 2011-02-02
US20090318411A1 (en) 2009-12-24
CA2721851A1 (en) 2009-12-03
CN102105474B (zh) 2014-01-08
RU2509081C2 (ru) 2014-03-10
WO2009146406A1 (en) 2009-12-03
RU2010154428A (ru) 2012-07-10

Similar Documents

Publication Publication Date Title
ES2533788T3 (es) Compuestos inhibidores de PI3K de tipo purina y métodos de uso
ES2644724T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
EP3056207B1 (en) Therapeutic compounds and related methods of use
ES2882797T3 (es) Inhibidores de dihidroorotato deshidrogenasa
ES2543567T3 (es) Métodos de utilización de inhibidores de ALK
CA2729725C (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
KR20160146807A (ko) Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법
RU2008145701A (ru) Производные пурина для применения в качестве агонистов аденозинового рецептора a2a
WO2017001853A1 (en) Antiviral compounds
RU2011100786A (ru) Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
CA2681250A1 (en) Chemical compounds
EP3119763A1 (en) Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
ES2875737T3 (es) Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos
AR066659A1 (es) Derivados de espiroindolinona
JP2011507851A (ja) Ｒｈｏキナーゼインヒビターとしてのベンゾイミダゾールおよびアナログ
ES2558608T3 (es) Derivados hetero-bicíclicos como inhibidores del VHC
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
AR084401A1 (es) COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS
KR20100051814A (ko) Ｇｐｒ１１９ ｇ 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물
KR20080107466A (ko) 대사 장애 치료용 8-헤테로아릴퓨린 ｍｎｋ2 억제제
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
RU2012134306A (ru) Азотосодержащие производные гетероарилов
ES2820553T3 (es) Compuesto y composición farmacéutica para trastorno neuropsicológico o tumor maligno
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina